Hansoh Pharma (Dual Glp-1/gip Receptor Agonist HS-20094) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Hansoh Pharma (Dual Glp-1/gip Receptor Agonist HS-20094) General Information

Description

Exclusive worldwide license to an investigational dual GLP-1/GIP receptor agonist. The medicine is a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Hong Kong
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Drug Discovery
Acquirer
Regeneron Pharmaceuticals
Corporate Office
  • Hong Kong

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Hansoh Pharma (Dual Glp-1/gip Receptor Agonist HS-20094) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Hansoh Pharma (Dual Glp-1/gip Receptor Agonist HS-20094)‘s full profile, request access.

Request a free trial

Hansoh Pharma (Dual Glp-1/gip Receptor Agonist HS-20094) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Hansoh Pharma (Dual Glp-1/gip Receptor Agonist HS-20094)‘s full profile, request access.

Request a free trial

Hansoh Pharma (Dual Glp-1/gip Receptor Agonist HS-20094) FAQs

  • Where is Hansoh Pharma (Dual Glp-1/gip Receptor Agonist HS-20094) headquartered?

    Hansoh Pharma (Dual Glp-1/gip Receptor Agonist HS-20094) is headquartered in Hong Kong.

  • What industry is Hansoh Pharma (Dual Glp-1/gip Receptor Agonist HS-20094) in?

    Hansoh Pharma (Dual Glp-1/gip Receptor Agonist HS-20094)’s primary industry is Buildings and Property.

  • Is Hansoh Pharma (Dual Glp-1/gip Receptor Agonist HS-20094) a private or public company?

    Hansoh Pharma (Dual Glp-1/gip Receptor Agonist HS-20094) is a Private company.

  • What is the current valuation of Hansoh Pharma (Dual Glp-1/gip Receptor Agonist HS-20094)?

    The current valuation of Hansoh Pharma (Dual Glp-1/gip Receptor Agonist HS-20094) is .

  • What is Hansoh Pharma (Dual Glp-1/gip Receptor Agonist HS-20094)’s current revenue?

    The current revenue for Hansoh Pharma (Dual Glp-1/gip Receptor Agonist HS-20094) is .

  • Who are Hansoh Pharma (Dual Glp-1/gip Receptor Agonist HS-20094)’s investors?

    Hansoh Pharma has invested in Hansoh Pharma (Dual Glp-1/gip Receptor Agonist HS-20094).

  • When was Hansoh Pharma (Dual Glp-1/gip Receptor Agonist HS-20094) acquired?

    Hansoh Pharma (Dual Glp-1/gip Receptor Agonist HS-20094) was acquired on 05-Jul-2025.

  • Who acquired Hansoh Pharma (Dual Glp-1/gip Receptor Agonist HS-20094)?

    Hansoh Pharma (Dual Glp-1/gip Receptor Agonist HS-20094) was acquired by Regeneron Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process